In patients with NSCLC, measuring the percentage of PD-L1-positive cancer cells in cancer tissues by immunohistochemistry (IHC) is useful for predicting the efficacy and application of anti-PD-1 and -PD-L1 therapeutic antibodies [7–9]. This evidence concerns the gene PDCD1 and cancer.